Profile
Peter Altman is the President and Chief Executive Officer of BioCardia, Inc., as disclosed in the company's SEC filings dated June 9, 2026. BioCardia is a biotechnology company focused on cardiovascular regenerative medicine and related cell therapies. The provided SEC filings establish his current leadership role but do not furnish a detailed public biography, educational background, or prior professional history within the filing context.
| Role | President and CEO, Director |
|---|
| Notability | 60/100 |
|---|
Board memberships
Awards & honors
- President and Chief Executive Officer of BioCardia, Inc. as of 2026-06-09 per SEC filings
Frequently Asked Questions
Who is Altman Peter?
Peter Altman is the President and Chief Executive Officer of BioCardia, Inc., as disclosed in the company's SEC filings dated June 9, 2026. BioCardia is a biotechnology company focused on cardiovascular regenerative medicine and related cell therapies. The provided SEC filings establish his current leadership role but do not furnish a detailed public biography, educational back…
How many SEC Form 4 filings has Altman Peter submitted recently?
11 primary Form 4 filings in the last 90 days, covering 1 company.
Has Altman Peter been buying or selling stock?
Recorded transactions: 31 open-market purchases ($164K) and 0 open-market sales () across all tracked filings.
How accurate is Altman Peter's historical track record?
Across 14 tracked purchases, Altman Peter averaged +549.6% avg 30-day return with a 6429% 30-day win rate. InsiderAlpha rates the track record at 3/5 stars.
Where can I see all of Altman Peter's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.